Skip to main content
Jim Tartaglia

Jim Tartaglia

Global Head of Development
Sanofi Vaccines

Jim Tartaglia is an internationally recognized vaccine R&D leader with over 30 years of experience in industry, including exposure to partnerships with private sector, government and international agencies. He is respected for creating and leading multidisciplinary teams to deliver business objectives and address complex problems, especially towards developing and licencing products in the veterinary and human vaccine areas. Jim is recognized for strong leadership, stakeholder engagement and team management skills within matrix organizations, with a proven track record in vaccine R&D, general management, project leadership, strategic planning and execution, and stakeholder relationship management.

Jim is currently Global Head of Development for Sanofi Vaccine and is based in Swiftwater, Pennsylvania, USA. In his over 30-year tenure with Sanofi, Jim has held positions of site head for R&D at the Toronto site and various portfolio leadership roles.

Before joining Sanofi Pasteur-Canada in 1999, Jim was Executive Director of Research at Virogenetics Corporation of Troy, New York, a former subsidiary of Sanofi Pasteur. At Virogenetics, he helped develop the poxvirus vector technology as an immunization vehicle for both veterinary and human application, including HIV and cancer.

Prior to joining Virogenetics in 1990, Jim worked as a research scientist with the New York State Department of Health and was a postdoctoral fellow at the Roche Institute of Molecular Biology in Nutley, New Jersey. He holds a PhD from the Department of Microbiology and Immunology at the Albany Medical College and a BSc in biology from Bucknell University in Lewisburg, Pennsylvania.

Jim is an inventor on over 20 patents relating to recombinant vaccines and has authored over 130 publications in the areas of molecular virology and recombinant vaccine technology. He participates as associate editor and/or reviewer for peer-reviewed journals. He also serves as expert contributor to faculty of 1,000.

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.